Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00451859 | Breast | Precancer | maintenance of protein location | 19/1080 | 94/18723 | 1.43e-06 | 5.35e-05 | 19 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
GO:00092667 | Breast | Precancer | response to temperature stimulus | 27/1080 | 178/18723 | 3.85e-06 | 1.21e-04 | 27 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
GO:00324968 | Breast | Precancer | response to lipopolysaccharide | 41/1080 | 343/18723 | 7.94e-06 | 2.17e-04 | 41 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00456379 | Breast | Precancer | regulation of myeloid cell differentiation | 28/1080 | 210/18723 | 3.05e-05 | 6.72e-04 | 28 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
GO:00713568 | Breast | Precancer | cellular response to tumor necrosis factor | 28/1080 | 229/18723 | 1.42e-04 | 2.45e-03 | 28 |
GO:00346128 | Breast | Precancer | response to tumor necrosis factor | 29/1080 | 253/18723 | 3.32e-04 | 4.70e-03 | 29 |
GO:00712227 | Breast | Precancer | cellular response to lipopolysaccharide | 25/1080 | 209/18723 | 4.41e-04 | 5.85e-03 | 25 |
GO:00712167 | Breast | Precancer | cellular response to biotic stimulus | 28/1080 | 246/18723 | 4.67e-04 | 6.14e-03 | 28 |
GO:00725948 | Breast | Precancer | establishment of protein localization to organelle | 41/1080 | 422/18723 | 7.75e-04 | 9.20e-03 | 41 |
GO:00712197 | Breast | Precancer | cellular response to molecule of bacterial origin | 25/1080 | 221/18723 | 1.00e-03 | 1.12e-02 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516310 | Stomach | GC | Human cytomegalovirus infection | 33/708 | 225/8465 | 9.98e-04 | 7.42e-03 | 5.23e-03 | 33 |
hsa051708 | Stomach | GC | Human immunodeficiency virus 1 infection | 30/708 | 212/8465 | 2.91e-03 | 1.76e-02 | 1.24e-02 | 30 |
hsa0513510 | Stomach | GC | Yersinia infection | 20/708 | 137/8465 | 9.77e-03 | 4.96e-02 | 3.49e-02 | 20 |
hsa0517113 | Stomach | GC | Coronavirus disease - COVID-19 | 71/708 | 232/8465 | 2.32e-23 | 3.72e-21 | 2.62e-21 | 71 |
hsa0520813 | Stomach | GC | Chemical carcinogenesis - reactive oxygen species | 65/708 | 223/8465 | 3.46e-20 | 2.72e-18 | 1.91e-18 | 65 |
hsa0513013 | Stomach | GC | Pathogenic Escherichia coli infection | 43/708 | 197/8465 | 2.99e-09 | 6.39e-08 | 4.50e-08 | 43 |
hsa0516613 | Stomach | GC | Human T-cell leukemia virus 1 infection | 41/708 | 222/8465 | 9.06e-07 | 1.71e-05 | 1.20e-05 | 41 |
hsa0541713 | Stomach | GC | Lipid and atherosclerosis | 40/708 | 215/8465 | 1.01e-06 | 1.80e-05 | 1.27e-05 | 40 |
hsa051341 | Stomach | GC | Legionellosis | 17/708 | 57/8465 | 2.28e-06 | 3.83e-05 | 2.70e-05 | 17 |
hsa0513213 | Stomach | GC | Salmonella infection | 42/708 | 249/8465 | 7.57e-06 | 1.05e-04 | 7.41e-05 | 42 |
hsa051451 | Stomach | GC | Toxoplasmosis | 22/708 | 112/8465 | 1.22e-04 | 1.22e-03 | 8.56e-04 | 22 |
hsa0516913 | Stomach | GC | Epstein-Barr virus infection | 33/708 | 202/8465 | 1.35e-04 | 1.31e-03 | 9.22e-04 | 33 |
hsa0516713 | Stomach | GC | Kaposi sarcoma-associated herpesvirus infection | 31/708 | 194/8465 | 3.20e-04 | 2.93e-03 | 2.06e-03 | 31 |
hsa051401 | Stomach | GC | Leishmaniasis | 16/708 | 77/8465 | 5.21e-04 | 4.63e-03 | 3.26e-03 | 16 |
hsa0513113 | Stomach | GC | Shigellosis | 36/708 | 247/8465 | 6.74e-04 | 5.42e-03 | 3.82e-03 | 36 |
hsa046571 | Stomach | GC | IL-17 signaling pathway | 18/708 | 94/8465 | 6.78e-04 | 5.42e-03 | 3.82e-03 | 18 |
hsa051641 | Stomach | GC | Influenza A | 27/708 | 171/8465 | 9.20e-04 | 7.01e-03 | 4.94e-03 | 27 |
hsa0516311 | Stomach | GC | Human cytomegalovirus infection | 33/708 | 225/8465 | 9.98e-04 | 7.42e-03 | 5.23e-03 | 33 |
hsa0517011 | Stomach | GC | Human immunodeficiency virus 1 infection | 30/708 | 212/8465 | 2.91e-03 | 1.76e-02 | 1.24e-02 | 30 |
hsa0513511 | Stomach | GC | Yersinia infection | 20/708 | 137/8465 | 9.77e-03 | 4.96e-02 | 3.49e-02 | 20 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN | CHEMBL401565 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | 6-METHOXYCOMAPARVIN 5-METHYL ETHER | CHEMBL256967 | 18088098 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DEMETHYLWEDELOLACTONE | DEMETHYLWEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | GAMBOGIC ACID | GAMBOGIC ACID | 22472167 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 31664190 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | (+)-TUBERIFERIN | CHEMBL1940084 | 22153345 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | WEDELOLACTONE | WEDELOLACTONE | 22926226 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | DIOSCIN | DIOSCIN | 23621869 |
4792 | NFKBIA | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR BINDING, DRUGGABLE GENOME | | PEPEROMIN E | PEPEROMIN E | 19559609 |